Researchers dig into how myeloid cells contribute to killing cancer
WASHINGTON, DC - Dr. Miriam Merad, PhD, director of the Precision Immunology Institute at the Icahn School of Medicine at Mount Sinai is working on characterizing myeloid cells in cancer patients. Merad spoke with ScienceBoard at the Society for Immunotherapy of Cancer's 2021 annual meeting. Read More
New neoadjuvant platform helps inform combo immunotherapy selection for cancers
WASHINGTON, DC - In order to address some of the major challenges facing the immuno-oncology field, Dr. Tom Marron, PhD, has developed a platform to help researchers decide which drugs or combination of drugs to advance toward late-stage clinical trials. Marron spoke with ScienceBoard Editor in Chief, Samantha Black, PhD, onsite at the Society for Immunotherapy of Cancer's 2021 annual meeting. Read More
Illumina for Startups pushes boundaries of genomics by supporting early-stage companies
Most scientists are familiar with the genomics giant Illumina, which is known for its DNA sequencing technologies. However, Illumina has an accelerator program to support early-stage startups called Illumina for Startups. ScienceBoard.net recently spoke with Amanda Cashin, PhD, who leads Illumina's accelerator programs in the U.S. and internationally. Read More
$2.7B oncology cell and gene therapy market projected for 2021
The global market for oncology cell and gene therapies reached $1.6 million in 2020 and is expected to reach $2.744 billion in 2021, according to a recent article in Cell and Gene Therapy Business Outlook, a sister subscription-based publication of ScienceBoard.net. Read More
Can cell therapies treat cardiovascular disease?
While the development of cell therapies today is largely focused on oncology indications, some companies, including Athersys, envision a future where these therapies could treat other diseases and conditions, such as cardiovascular disease. B.J. Lehmann, interim CEO of Athersys, spoke with ScienceBoard.net about a recent panel that he participated in at the Cell & Gene Meeting on the Mesa 2021. Read More
Cellaria launches new tumor modeling platform
Cellaria has launched a new tumor modeling platform that includes a panel of cell culture media for growing cell types, an extracellular neutral collagen matrix, and protocols for testing new drug compounds. Read More
Worm that regrows its body parts can be a 'powerful system' for life sciences research
Scientists have demonstrated that Hofstenia miamia, a tiny flatworm capable of regenerating everything from its brain down to its tail, can be a powerful tool to study not only regeneration but other areas such as embryogenesis. The findings were published on November 8 in the journal Developmental Cell. Read More
EY white paper details how the CGT industry can collaborate to advance the field
A transition from corporate individualism to teamwork and collaboration is necessary to meet the challenges that exist for companies in the cell and gene therapy (CGT) industry, according to a new white paper published by Ernst & Young (EY) on November 4. Read More
Experimental drug enhances immunotherapy against pancreatic cancer in mice
A combination treatment that included an experimental small molecule drug not only led to a reduction in tumor growth in murine models of pancreatic cancer, but it also eliminated the cancer in some mice. The findings were published in the Journal for ImmunoTherapy of Cancer on November 4. Read More
Online portal helps screen COVID-19 drug candidates
An interdisciplinary team of engineers and scientists has released DINC-COVID, a web-based portal where researchers can screen COVID-19 drug candidates that might attack specific SARS-CoV-2 proteins. Details of the new platform were published online in Computers in Biology and Medicine. Read More
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter